Current GenomicsBioinformaticsPeer-reviewed journal article
Identification of conserved epitopes in SARS-CoV-2 spike and nucleocapsid protein.
Sergio ForcelloniiD, Anna BenedettiiD, Maddalena DiluccaiD, Andrea GiansantiiD
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which first occurred in Wuhan (China) in December 2019, is a novel virus that causes a severe acute respiratory disease. The virus spike glycoproteins and nucleocapsid proteins are the main targets for the development of vaccines and antiviral drugs, to control the disease spread. We herein study the structural order-disorder propensity and the rates of evolution of these two proteins to characterize their B cell and T cell epitopes, previously suggested to contribute to immune response caused by SARS-CoV-2 infections. We first analyzed the rates of evolution along the sequences of spike and nucleocapsid proteins in relation to the spatial locations of their epitopes. For this purpose, we compared orthologs from seven human coronaviruses: SARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1. We then focus on the local, structural order-disorder propensities of the protein regions where the SARS-CoV-2 epitopes are located. We show that the vast majority of nucleocapsid protein epitopes overlap the RNA-binding and dimerization domains and some of them are characterized by low rates of evolutions. Similarly, spike protein epitopes are preferentially located in regions that are predicted to be ordered and well-conserved, in correspondence of the heptad repeats 1 and 2. Interestingly, both the receptor-binding motif to ACE2 and the fusion peptide of spike protein are characterized by high rates of evolution, probably to overcome host immunity. In conclusion, our results provide evidence for conserved epitopes that may help to develop long-lasting, broad-spectrum SARS-CoV-2 vaccines.
- organism: human
- assay: protein structure
- research focus: protein structure prediction
- approach: statistical model
- Citations
- 16
- FWCI
- 0.87
- Field percentile
- top 22%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Antigenic variation of SARS-CoV-2 in response to immune pressure
D. Forni, R. Cagliani, … M. Sironi·bioRxiv·Jul 15, 2020
- Peptidome Surveillance Across Evolving SARS-CoV-2 Lineages Reveals HLA Binding Conservation in Nucleocapsid Among Variants With Most Potential for T-Cell Epitope Loss In Spike
K. Wnuk, J. Sudol, … P. Soon-Shiong·bioRxiv·Mar 18, 2022
- Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies
Syed Faraz Ahmed, Ahmed Abdul Quadeer, Matthew R. McKay·VirusesPeer-reviewed·Feb 25, 2020
- Insights into Cross-species Evolution of Novel Human Coronavirus SARS-CoV-2 and Defining Immune Determinants for Vaccine Development
A. Ramaiah, V. Arumugaswami·bioRxiv·Jan 29, 2020
- Immune Epitopes of SARS-CoV-2 Spike Protein and Considerations for Universal Vaccine Development
N. Magazine, T. Zhang, … W. Huang·bioRxiv·Oct 26, 2023
- Genome based Evolutionary study of SARS-CoV-2 towards the Prediction of Epitope Based Chimeric Vaccine
M. R. N. Akhand, K. F. Azim, … M. Hasan·bioRxiv·Apr 15, 2020